The number of people making five or more emergency visits to hospital a year with lung difficulties has almost tripled in some parts of England, an analysis has found. The charity Asthma + Lung UK ...

China: Severe asthma remains a major healthcare challenge, contributing to increased morbidity, reduced quality of life, and ...

This study supports the National Asthma Education and Prevention Program guidelines for step-up therapy with LABAs for asthma that is uncontrolled on low-dose ICS. The study was not large enough ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License ...

US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps: London, UK Tuesday, March 4, 2025, 09:0 ...

Inhaled corticosteroids (ICS) are the most effective anti-inflammatory drug. In childhood and adult asthma, early intervention with ICS could facilitate better control of asthma symptoms.

Depemokimab’s PDUFA date is set for December 16, 2025, with FDA reviewing two indications. Phase 3 trials showed significant improvements in nasal polyp size and obstruction. Join Nic Chahine ...

Many inhalers that are vital for patients with asthma or COPD are associated with societal harms that can worsen the very diseases the products are designed to treat. How can this dilemma be resolved?

Taking to social media, Inhaler said they were 'gutted' to be postponing the performance, and reassured fans they would be returning "very soon". Unfortunately the 2.21pm announcement, just hours ...